Joanne E. Tomassini
Isis Pharmaceuticals
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Joanne E. Tomassini.
Journal of Biological Chemistry | 2003
Steven S. Carroll; Joanne E. Tomassini; Michele Bosserman; Krista Getty; Mark Stahlhut; Anne B. Eldrup; Balkrishen Bhat; Dawn L. Hall; Amy L. Simcoe; Robert L. Lafemina; Carrie A. Rutkowski; Bohdan Wolanski; Zhucheng Yang; Giovanni Migliaccio; Raffaele De Francesco; Lawrence C. Kuo; Malcolm Maccoss; David B. Olsen
The RNA-dependent RNA polymerase (NS5B) of hepatitis C virus (HCV) is essential for the replication of viral RNA and thus constitutes a valid target for the chemotherapeutic intervention of HCV infection. In this report, we describe the identification of 2′-substituted nucleosides as inhibitors of HCV replication. The 5′-triphosphates of 2′-C-methyladenosine and 2′-O-methylcytidine are found to inhibit NS5B-catalyzed RNA synthesis in vitro, in a manner that is competitive with substrate nucleoside triphosphate. NS5B is able to incorporate either nucleotide analog into RNA as determined with gel-based incorporation assays but is impaired in its ability to extend the incorporated analog by addition of the next nucleotide. In a subgenomic replicon cell line, 2-C-methyladenosine and 2′-O-methylcytidine inhibit HCV RNA replication. The 5′-triphosphates of both nucleosides are detected intracellularly following addition of the nucleosides to the media. However, significantly higher concentrations of 2′-C-methyladenosine triphosphate than 2′-O-methylcytidine triphosphate are detected, consistent with the greater potency of 2′-C-methyladenosine in the replicon assay, despite similar inhibition of NS5B by the triphosphates in the in vitroenzyme assays. Thus, the 2′-modifications of natural substrate nucleosides transform these molecules into potent inhibitors of HCV replication.
Antimicrobial Agents and Chemotherapy | 2004
David B. Olsen; Anne B. Eldrup; Linda Bartholomew; Balkrishen Bhat; Michele Bosserman; Alessandra Ceccacci; Lawrence F. Colwell; John F. Fay; Osvaldo A. Flores; Krista Getty; Jay A. Grobler; Robert L. Lafemina; Eric J. Markel; Giovanni Migliaccio; Marija Prhavc; Mark Stahlhut; Joanne E. Tomassini; Malcolm Maccoss; Daria J. Hazuda; Steven S. Carroll
ABSTRACT Improved treatments for chronic hepatitis C virus (HCV) infection are needed due to the suboptimal response rates and deleterious side effects associated with current treatment options. The triphosphates of 2′-C-methyl-adenosine and 2′-C-methyl-guanosine were previously shown to be potent inhibitors of the HCV RNA-dependent RNA polymerase (RdRp) that is responsible for the replication of viral RNA in cells. Here we demonstrate that the inclusion of a 7-deaza modification in a series of purine nucleoside triphosphates results in an increase in inhibitory potency against the HCV RdRp and improved pharmacokinetic properties. Notably, incorporation of the 7-deaza modification into 2′-C-methyl-adenosine results in an inhibitor with a 20-fold-increased potency as the 5′-triphosphate in HCV RdRp assays while maintaining the inhibitory potency of the nucleoside in the bicistronic HCV replicon and with reduced cellular toxicity. In contrast, while 7-deaza-2′-C-methyl-GTP also displays enhanced inhibitory potency in enzyme assays, due to poor cellular penetration and/or metabolism, the nucleoside does not inhibit replication of a bicistronic HCV replicon in cell culture. 7-Deaza-2′-C-methyl-adenosine displays promising in vivo pharmacokinetics in three animal species, as well as an acute oral lethal dose in excess of 2,000 mg/kg of body weight in mice. Taken together, these data demonstrate that 7-deaza-2′-C-methyl-adenosine is an attractive candidate for further investigation as a potential treatment for HCV infection.
Antimicrobial Agents and Chemotherapy | 2005
Joanne E. Tomassini; Krista Getty; Mark Stahlhut; Sung Shim; Balkrishen Bhat; Anne B. Eldrup; Thazha P. Prakash; Steven S. Carroll; Osvaldo A. Flores; Malcolm Maccoss; Daniel R. McMasters; Giovanni Migliaccio; David B. Olsen
ABSTRACT Nucleosides have been widely used in the treatment of viral diseases, but relatively few have been identified as inhibitors of hepatitis C virus (HCV). The modified ribonucleosides, 2′-C-methyl-adenosine and 2′-O-methyl-cytidine, are potent inhibitors of HCV replication which specifically target the NS5B polymerase. Herein, a more extensive characterization of the effect of these compounds upon HCV replication in subgenomic replicons is reported. A highly selective antireplicative effect induced by the nucleosides in replicon-containing cell lines was maintained during an exponential growth period with potencies which paralleled the reduction of both positive- and negative-strand RNA replication. Moreover, the inhibitory effect closely correlated with the intrinsic metabolic properties of differing replicon clonal lines. Interestingly, while 2′-C-methyl-adenosine elicited similar inhibitory potencies in different cell lines, 2′-O-methyl-cytidine was found to be inactive in one replicon cell line tested, although the corresponding triphosphates comparably inhibited the in vitro activity of replication complexes isolated from these cells and the activity of NS5B polymerase using synthetic templates. The lack of antireplicative effect, attributed to poor intracellular conversion of the 2′-O-methyl-cytidine nucleoside to the active 5′-triphosphate, was reversed using a monophosphate prodrug. Thus, although replicon cells are useful for evaluating the effect of inhibitors upon HCV replication, these findings have important implications for their use in the identification and characterization of nucleosides and other chemotherapeutic agents requiring cellular metabolism.
Journal of Biological Chemistry | 2003
Giovanni Migliaccio; Joanne E. Tomassini; Steven S. Carroll; Licia Tomei; Sergio Altamura; Balkrishen Bhat; Linda Bartholomew; Michele Bosserman; Alessandra Ceccacci; Lawrence F. Colwell; Riccardo Cortese; Raffaele De Francesco; Anne B. Eldrup; Krista Getty; Xiaoli S. Hou; Robert L. Lafemina; Steven W. Ludmerer; Malcolm Maccoss; Daniel R. McMasters; Mark Stahlhut; David B. Olsen; Daria J. Hazuda; Osvaldo A. Flores
Journal of Medicinal Chemistry | 2004
Anne B. Eldrup; Charles Allerson; C. Frank Bennett; Sanjib Bera; Balkrishen Bhat; Neelima Bhat; Michele Bosserman; Jennifer L. Brooks; Christine Burlein; Steven S. Carroll; P. Dan Cook; Krista Getty; Malcolm Maccoss; Daniel R. McMasters; David B. Olsen; Thazha P. Prakash; Marija Prhavc; Quanlai Song; Joanne E. Tomassini; Jie Xia
Journal of Medicinal Chemistry | 2004
Anne B. Eldrup; Marija Prhavc; Jennifer L. Brooks; Balkrishen Bhat; Thazha P. Prakash; Quanlai Song; Sanjib Bera; Neelima Bhat; Prasad Dande; P. Dan Cook; C. Frank Bennett; Steven S. Carroll; Richard G. Ball; Michele Bosserman; Christine Burlein; Lawrence F. Colwell; John F. Fay; Osvaldo A. Flores; Krista Getty; Robert L. Lafemina; Joseph F. Leone; Malcolm Maccoss; Daniel R. McMasters; Joanne E. Tomassini; Derek Von Langen; and Bohdan Wolanski; David B. Olsen
Proceedings of the National Academy of Sciences of the United States of America | 1999
Osvaldo A. Flores; Gary Lee; Joseph Kessler; Michael I. Miller; William Schlief; Joanne E. Tomassini; Daria J. Hazuda
Journal of Medicinal Chemistry | 2005
Thazha P. Prakash; Marija Prhavc; Anne B. Eldrup; P. Dan Cook; Steven S. Carroll; David B. Olsen; Mark Stahlhut; Joanne E. Tomassini; Malcolm Maccoss; Sheila M. Galloway; Catherine Hilliard; Balkrishen Bhat
Archive | 2004
David B. Olsen; Joanne E. Tomassini; Shi-shan Mao; Steven S. Carroll
Archive | 2002
Haoyun An; Balkrishen Bhat; Neelima Bhat; Steven S. Carroll; Phillip Dan Cook; Anne B. Eldrup; Charles John Guinosso; Dawn L. Hall; Amy L. Himmelberger; Lawrence C. Kuo; Robert L. Lafemina; Malcolm Maccoss; David B. Olsen; Thazha P. Prakash; Marija Prhavc; Carrie A. Rutkowski; Joanne E. Tomassini